In a retrospective cohort study, thirty-day mortality was lowest in SARS-CoV-2 residents taking metformin (12.6%, n = 12) compared with those on other diabetes medications (17.4%, n = 12), insulin (23.3%, n = 24), and no diabetes medications (22.7%, n = 108) [40]. This evidence concerns the gene INS and diabetes mellitus.